Physician profile
Patrick Murphy
NPI 1245449982
$768.72
in general payments reported to CMS, 2019-2025
22 companies · $99.10 in 2025
The $99.10 reported for 2025 was less than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.60 · 2022: $60.37 · 2023: $393 · 2024: $134 · 2025: $99.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $103.69 | 2023-2025 | Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $96.75 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Aveo Pharmaceuticals, INC. | $61.94 | 2023-2024 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $55.45 | 2023-2025 | Ninlaro, Iclusig |
| Genentech USA, INC. | $46.03 | 2019 | |
| Incyte Corporation | $39.15 | 2023-2024 | Monjuvi, Pemazyre |
| Pharmacosmos Therapeutics INC. | $39.10 | 2024 | Cosela |
| Tersera Therapeutics LLC | $35.74 | 2023 | Zoladex |
| Exelixis INC. | $31.53 | 2023-2024 | Cabometyx |
| Genzyme Corporation | $29.33 | 2022 | |
| Daiichi Sankyo INC. | $27.24 | 2023 | Enhertu |
| Servier Pharmaceuticals LLC | $24.66 | 2023 | |
| G1 Therapeutics, INC. | $23.99 | 2023 | Cosela |
| Genmab U.S., INC. | $23.93 | 2024 | Epkinly |
| Seagen INC. | $22.66 | 2023 | Tukysa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.33 | 2023 | |
| Sobi, INC | $16.96 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.84 | 2022 | |
| Morphosys, US INC. | $15.07 | 2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2023 | Opdivo |
| Abbvie INC. | $13.46 | 2019 | |
| Lilly USA, LLC | $13.38 | 2023 | Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.